Lv21
110 积分 2021-07-24 加入
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial
7小时前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
7小时前
已完结
Immunotherapy in Biliary Tract Cancers: Where Are We?
4个月前
已完结
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
11个月前
已完结
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial
1年前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
2年前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
2年前
已完结
肝癌转化治疗中国专家共识（2021版)
3年前
已完结
Radiofrequency ablation in the treatment of hepatocellular carcinoma
A Polycation Antimicrobial Peptide Mimic without Resistance Buildup against Propionibacterium Acnes
皖公网安备34019202002308
